All In Biotech

Drug Trial Radar · NCT06922318

The COSMYC Trial (COmbined Suppression of MYC)

A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 19, 2025

Primary completion

Aug 30, 2031

Study completion Aug 30, 2031

Sponsor

Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zenith Epigenetics; National Cancer Institute (NCI)
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • ZEN-3694Drug

    ZEN-3694 is available in two capsule strengths for this study: 12 mg and 48 mg.

  • Testosterone cypionateDrug

    On day 1 of each BATZEN cycle testosterone cypionate (400 mg) injection to the buttocks will be administered.

  • EnzalutamideDrug

    Enzalutamide 160 mg (four 40 mg tablets) taken daily by mouth on each ZENZA cycle.

  • Luteinizing hormone-releasing hormone (LHRH) analogueDrug

    Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical/radiographic progression free survival (PFS) with BATZENTime frame: 2 years
  2. Prostate specific antigen (PSA)-Progression free survival (PFS) with ZENZATime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.